<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115698</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2013-070.3</org_study_id>
    <nct_id>NCT02115698</nct_id>
  </id_info>
  <brief_title>Counteracting Age-related Loss of Skeletal Muscle Mass (CALM)</brief_title>
  <acronym>CALM</acronym>
  <official_title>Counteracting Age-related Loss of Skeletal Muscle Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 66 healthy elderly individuals (at least 65 years old) are recruited as subjects. They
      will be recruited as a subgroup to protocol ID: H-4-2013-070.

      Upon inclusion, each individual will be randomized into one of the five groups stratified
      according to gender (M/F) and 30s chair stand (&lt;16 OR ≥16). The five groups are: Heavy
      Resistance Training (N=12), Light Intensity Training (N=12), Protein Whey (N=15), Protein
      Collagen (N=15) and Carbohydrate (N=12). The individuals randomized into one of the
      supplementation groups (Protein Whey, Protein Collagen or Carbohydrate) will be blinded to
      the supplement content.

      Assessments will be performed at Baseline (before intervention start) and after 12 months of
      intervention.

      The primary outcomes are measures of muscle protein synthesis rate measured as the fractional
      synthesis rate from Baseline to 12 months of intervention.

      The hypotheses are i) that basal and protein-stimulated muscle protein synthesis rates are
      elevated in the exercise training groups after 12 months of intervention. ii) prolonged
      intake of protein of different quality will improve the muscle protein synthetic response to
      protein intake after 12 months of intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Basal overnight fasted muscle protein synthesis rate.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Overnight fasting muscle protein synthesis will be measured at Baseline and after 12 months intervention by applying stable isotope amino acid tracer techniques and calculating the fractional synthesis rates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle protein synthesis rate response to protein intake from basal overnight fasted state.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Change in the response of muscle protein synthesis rate to a single intake of 20 g whey protein and 10 g carbohydrate from the basal overnight fasted state from Baseline to 12 months intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle protein turnover molecular signaling and gene expression</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Muscle protein turnover regulation signaling and gene expression will be measured in the muscle tissue obtained for muscle protein synthesis measurements. Protein and protein activation status will be analysed by Western blot techniques. Gene expressions will be analysed by real time RT-PCR techniques.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light Intensity Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Whey</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Collagen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbohydrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two daily 30 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heavy Resistance Training</intervention_name>
    <description>Supervised Heavy Resistance Training three times weekly for 52 weeks.</description>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Light Intensity Training</intervention_name>
    <description>Home-based Light Intensity Training three-five times weekly for 52 weeks.</description>
    <arm_group_label>Light Intensity Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Whey</intervention_name>
    <description>Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
    <arm_group_label>Light Intensity Training</arm_group_label>
    <arm_group_label>Protein Whey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Collagen</intervention_name>
    <description>Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Protein Collagen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate</intervention_name>
    <description>Two daily 30 g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Carbohydrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, independently living

          -  Age at least 65 years

        Exclusion Criteria:

          -  Subjects dependent on help/nursing etc.

          -  Chronic medical diseases: diabetes mellitus, clinical knee or hip osteoarthritis,
             other types of arthritis or connective tissue disorders, active cancer, renal
             diseases, severe chronic obstructive pulmonary disease, cardiac arrhythmias or known
             decreased left ventricular ejection fraction, lactose or gluten intolerance, chronic
             inflammatory bowel diseases, non-treated hyper/hypothyroidism, dementia

          -  Surgical diseases: Bone, muscle, tendon or joint injuries compromising participation
             in exercise regimens

          -  Implanted magnetic devices incompatible with MRi-scanning

          -  Weekly alcohol consumption &gt; 21 units (1 unit equals 4 g of ethanol) for men and &gt; 14
             for women

          -  Medicine except acetylsalicylic acid, paracetamol, thyroid function hormones, statins
             in doses above 40 mg/day or if combined with subjective myalgia, ACE-inhibitors,
             angiotensin II blockers, beta-blockers, calciumantagonists, proton-pump inhibitors,
             thiazides, potassium-sparring diuretics and loop diuretics

          -  1 hour of exercise weekly, except light activities such as stretching/gymnastics and
             bike-riding/walking as transportation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus L. Bechshoeft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Holm, assoc. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kjaer, MD, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren Reitelseder, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob Bülow, MD PhD stud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob L. Bülow, MD</last_name>
    <phone>+45 38 35366</phone>
    <email>jacob.bulow@live.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Søren Reitelseder, PhD</last_name>
    <phone>+45 38 35366</phone>
    <email>s.reitelseder@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Bülow, MD</last_name>
      <phone>+45 38 35366</phone>
      <email>jacob.bulow@live.dk</email>
    </contact>
    <contact_backup>
      <last_name>Søren Reitelseder, PhD</last_name>
      <phone>+45 38 35366</phone>
      <email>s.reitelseder@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jacob Bülow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Holm, PhD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Søren Reitelseder, PhD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Lars Holm</investigator_full_name>
    <investigator_title>PhD, MS</investigator_title>
  </responsible_party>
  <keyword>Sarcopenia</keyword>
  <keyword>Frailty</keyword>
  <keyword>Ageing</keyword>
  <keyword>Protein supplementation</keyword>
  <keyword>Protein quality</keyword>
  <keyword>Exercise training</keyword>
  <keyword>Muscle protein turnover</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

